GlobeImmune initiates Phase I trial of GI-6301
Brachyury is over-expressed in a variety of important tumor types including breast, colon, lung and prostate cancers. The primary endpoint of open-label study is the safety and tolerability
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).
The new office will incorporate the company’s commercialization team handling, while retaining its corporate headquarters, with clinical, manufacturing, regulatory and administration functions, remains in Dublin, Ohio, US. Navidea